ISSN:
1432-0584
Keywords:
Key words Interleukin-2
;
Acute myeloid leukemia
;
Leukocytoclastic vasculitis
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01700380
Permalink